NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Evolus, Inc. EOLS
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$297.2M
▲ 11.6% vs FY2024
EPS · FY25
$-0.80
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-17.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 297.2M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 17 cents on every revenue dollar this year.
Per share
USD -0.80
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-11.0%
Net margin-17.4%
Return on assets-22.5%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+39.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+26.0%
+39.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 225.9M
total assets, end of FY2025
Total assetsUSD 225.9M
EquityUSD -23.1M
CashUSD 53.8M
Gross debtUSD 146.1M
Net debtUSD 92.3M
Current ratio1.90×
Net debt stands at -399% of equity.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.3
0.3
0.2
0.1
0.1
0.1
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.1
−0.0
−0.2
−0.1
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.1
−0.0
−0.1
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.0
−0.2
−0.1
−0.0
−0.0
EPS, diluted $
−0.80
−0.81
−1.08
−1.33
−0.94
−4.83
−3.19
−1.92
−0.27
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
−148.3
−1049.8
−5016.6
−109.9
−1060.2
·
Shares out B
0.07
0.06
0.06
0.06
0.06
0.03
0.03
0.03
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
33 of 33
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed